Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis

Tarinee Rungjirajittranon, Weerapat Owattanapanich, Yingyong Chinthammitr, Theera Ruchutrakool and Bundarika Suwanawiboon*

Abstract

Background: The association between gastrointestinal (GI) cancer and a high incidence of venous thromboembolism (VTE) is well known. Previous randomized controlled studies demonstrated that direct oral anticoagulants (DOACs) effectively treat cancer-associated thrombosis (CAT). However, some DOACs appeared to increase the risk of bleeding, particularly in patients with GI malignancies. Therefore, the current systematic review and meta-analysis were conducted to evaluate the safety and efficacy of DOACs in GI cancer-associated thrombosis.

Methods: Two investigators individually reviewed all studies that compared DOACs and low-molecular-weight heparins (LMWHs) in GI cancer-associated thrombosis and were published in MEDLINE and EMBASE before February 2022. The effect estimates and 95% confidence intervals (CIs) from each eligible study were combined using the Mantel–Haenszel method.

Results: A total of 2226 patients were included in the meta-analysis. The rates of major bleeding in the DOAC and LMWH groups were not significantly different (relative risk [RR]: 1.31; 95% CI: 0.84–2.04; \( P = 0.23; I^2 = 41\% \)). However, the rate of clinically relevant nonmajor bleeding (CRNMB) was significantly higher in the DOAC group (RR: 1.76; 95% CI: 1.24–2.52; \( P = 0.002; I^2 = 8\% \)). The risks of recurrent VTE in the groups did not significantly differ (RR: 0.72; 95% CI: 0.49–1.04; \( P = 0.08; I^2 = 0\% \)).

Conclusions: The current data suggest that treatment of GI cancer-associated thrombosis with DOACs significantly increases the risk of CRNMB. However, the risk of major bleeding was not significantly different. The efficacy of DOACs for preventing recurrent VTE in GI cancer was comparable to that of LMWHs.

Trial registration: INPLASY202180113.

*Correspondence: bundarika.suw@mahidol.ac.th
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
**Background**

The relationship between cancer and thrombosis is well recognized. A recent population-based study showed that the cumulative incidence of venous thromboembolism (VTE) after cancer diagnosis was 11.1-fold higher than that in noncancer patients [1]. Moreover, VTE is among the leading causes of death in cancer patients [2]. The absolute rate of VTE in all cancers from a large United Kingdom database was 13.9 per 1000 person-years [3, 4]. A study in the East Asian population revealed an incidence of cancer-associated VTE of 9.9 per 1000 person-years in hepatocellular and pancreatic cancers [5].

In addition to ethnicity and cancer stage, the type of cancer also influences the risk of thrombosis. Gastrointestinal (GI) cancer (cancers of the pancreas, stomach, liver, colon, and rectum) is among the top 4 most prevalent cancers worldwide [6, 7]. A higher incidence of VTE was found in patients with GI cancer than in those without GI cancer [8, 9]. Singh R et al. reported that 60 of 220 (27.3%) patients with GI cancer experienced 83 thromboembolic events, including 38.6% deep vein thrombosis and 20.5% pulmonary embolism [9]. Interestingly, some of those patients experienced more than 1 thrombotic event, and some thromboses were incidentally found [9].

The treatment of cancer-associated thrombosis has vastly improved in recent years. Direct oral anticoagulants (DOACs) have become a standard treatment for VTE in patients with cancer. Their use is based on evidence from randomized controlled studies that compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWHs) [10–13]. Even though the benefit of DOACs in preventing recurrent thrombosis has been demonstrated in patients with cancer, the risk of bleeding is a drawback, especially in patients with GI malignancies. The Hokusai VTE Cancer trial found that major bleeding events among patients with GI cancer treated with edoxaban were significantly more frequent than for the dalteparin arm (13.2% vs 2.4%; P = 0.0169) [10]. In the SELECT-D study, patients with esophageal or gastroesophageal cancer receiving rivaroxaban tended to experience more major bleeding than those treated with dalteparin (36% vs 5%). Consequently, the recruitment of patients with this tumor type was stopped in the ongoing trial [11]. In contrast, the incidence of bleeding events, particularly in patients with GI malignancies, did not significantly differ between the apixaban and dalteparin arms in the ADAM VTE and Caravaggio trials [12, 13].

The present systematic review and meta-analysis aimed to improve our understanding of the efficacy and safety of DOACs in treating acute VTE in patients with GI cancer compared with LMWHs. To this end, a comprehensive identification was made of all available studies, and their data were summarized and analyzed.

**Methods**

**Data sources and searches**

All relevant studies that compared DOACs and LMWHs in GI cancer-associated thrombosis and were published before February 2022 were identified in 2 databases (MEDLINE and EMBASE). The search terms were “DOACs,” “anticoagulants,” and “GI cancer” (Additional file 1: Supplementary Data 1). Two investigators (TR and WO) separately examined the included articles. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement guided the meta-analysis (Additional file 2: Supplementary Data 2) [14]. The study protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (registration number INPLASY202180113).

**Selection criteria and data extraction**

The inclusion criteria for this meta-analysis were as follows: (1) the type of study must have been a randomized controlled trial (RCT) or a cohort study (either retrospective or prospective); (2) the study must have compared the efficacy of at least 1 DOAC and at least 1 LMWH in GI cancer-associated venous thromboembolism; (3) the study must have included the primary outcome; and (4) the study must have defined “major bleeding” according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH) [15].

The same 2 investigators (TR and WO) independently selected relevant articles and extracted data. If there was any disagreement or question regarding the eligibility of an article, a third investigator (BS) made the final decision. The 2 investigators (TR and WO) examined the baseline characteristics data and the outcomes of all included studies. The extracted data were cross-checked to avoid inaccuracies.

**Outcome definitions**

The primary outcome was either recurrent VTE or major bleeding after anticoagulant therapy, as defined by the ISTH criteria [15]. “Major bleeding” encompassed fatal bleeding, symptomatic bleeding in a critical area or...
organ, and bleeding causing a decrease in hemoglobin level of ≥ 2 g/dL or leading to the transfusion of ≥ 2 units of whole blood or red cells [15].

The secondary outcome was clinically relevant nonmajor bleeding (CRNMB). The studies in this meta-analysis used a variety of definitions of CRNMB. They are detailed in Additional file 3: Supplementary Data 3.

Quality assessment
The “Cochrane Risk-of-Bias Tool for Randomized Trials” (ROB-2) [16] and the “Risk of Bias in Non-Randomized Studies of Interventions” (ROBINS-I) [17] were used to evaluate the quality of the included studies.

Statistical analysis
Review Manager 5.3 software from the Cochrane Collaboration (London, UK) was used to analyze the data. Two investigators (TR and WO) extracted data from the selected studies using a standardized data extraction form. The effect was estimated and combined with 95% confidence intervals (CIs) using the Mantel–Haenszel method [18]. Cochran's Q test was calculated, and the statistical heterogeneity among the studies was estimated using the I² statistic. The 4 levels of heterogeneity were based on the value of I² as follows: (1) insignificant heterogeneity (values of 0%–25%); (2) low heterogeneity (values of 26%–50%); (3) moderate heterogeneity (values of 51%–75%); and (4) high heterogeneity (values of 76%–100%) [19]. The random-effects model was applied based on the assumption that there was heterogeneity in the studies due to differing patient characteristics, DOACs, and types of GI cancers [19]. A probability (P) value less than 0.05 was considered statistically significant.

Subgroup analyses
Subgroup analyses were based on the type of study to avoid heterogeneity and bias. Moreover, to determine the differences in bleeding risks and VTE recurrence related to each type of GI cancer and DOAC, we analyzed subgroups of patients according to GI cancer (luminal or nonluminal) and DOAC subtype.

Results
Study identification and selection
An electronic search of the MEDLINE and EMBASE databases revealed 1279 potentially relevant articles. After excluding 170 duplicate articles, 2 investigators reviewed the titles and abstracts of the remaining 1109 articles. Of those, 1069 articles were excluded if they met at least 1 of the following 3 criteria:

1. The articles were reviews, meta-analyses, commentaries, or editorials.
2. The reports were irrelevant to the comparison between DOACs and LMWHs.
3. The reports described a study population different from that evaluated in our study.

A total of 40 full-length articles were identified. Of those, 29 articles were excluded due to insufficient data or a lack of clinical outcomes. The remaining 11 articles (6 RCTs and 5 retrospective studies) collectively enrolled 2226 patients. Six articles evaluated edoxaban, 6 examined rivaroxaban, and 6 assessed apixaban. All 11 articles were included in the present meta-analysis. Figure 1 illustrates the literature review and article selection process.

Baseline characteristics
The 11 studies had a combined total of 2226 patients. In the DOAC group, only direct Xa inhibitors were used, with 165 patients given edoxaban [20, 27], 368 receiving rivaroxaban [11, 21–23, 27–29], and 412 using apixaban [23–29]. However, 140 patients had no details of their DOAC subtype [27, 29]. As for LMWHs, 1141 patients received them. Dalteparin was used with 693 patients, enoxaparin with 447 patients, and nadroparin with 1 patient [11, 20–29].

Regarding the type of GI cancer, 526 patients had upper GI cancer (cancer of the esophagus or stomach), 945 had lower GI cancer (cancer of the colon or rectum), 740 had hepatobiliary-pancreatic cancer (hepatocellular carcinoma, cholangiocarcinoma, cancer of the gallbladder, or pancreatic cancer), and 7 had neuroendocrine tumors. These patients were also subdivided into 3 groups. Group 1 had 1471 patients with luminal GI cancer (cancer of the esophagus, stomach, colon, or rectum) [11, 20–29]. Group 2 had 740 patients with nonluminal GI cancer (hepatocellular carcinoma, cancer of the gallbladder, or pancreatic cancer) [11, 20–29]. Group 3 had 7 patients with neuroendocrine tumors [23].

The studies’ follow-up periods ranged from 6 to 12 months [11, 20–29]. The characteristics of the recruited patients are summarized in Table 1, while Fig. 2 presents the risk-of-bias plot of the studies.

Clinical bleeding outcome
Six randomized controlled trials and 5 retrospective studies compared DOACs with LMWHs. Major bleeding was defined according to the ISTH criteria [15]; in the Caravaggio study, it was combined with “bleeding resulting in surgical intervention” [13]. Our pooled analysis showed a nonsignificantly higher risk of major bleeding in patients receiving DOACs than in those receiving LMWHs, with a pooled relative risk (RR) of 1.31. However, the pooled effect estimate did not reach statistical significance (95% CI: 0.84–2.04; P=0.23).
Furthermore, the heterogeneity of the meta-analysis was low, with an I² value of 41% (Fig. 3) [11, 20–24, 26–29]. In contrast, the incidence of CRNMB was significantly higher in the DOAC group than in the LMWH group, with a pooled RR of 1.76 (95% CI: 1.24–2.52; \( P = 0.002; \) I² = 8%; Fig. 4) [11, 21, 22, 24, 28, 29].

**Location of bleeding**

Four studies reported the locations of major bleeding in patients with GI cancer treated with DOACs [22, 24, 29, 30]. Of 50 bleeding events, 41 occurred in the GI tract. The central nervous system, genitourinary tract, retroperitoneal areas, upper airway, epistaxis, vagina, and muscle hematoma were other bleeding sites. The details of major bleeding and the type of anticoagulant therapy are listed in Table 2.

**Recurrent VTE outcome**

The rates of recurrent VTE in patients who received DOACs and those who received LMWHs were not significantly different, with a pooled RR of 0.72 (95% CI: 0.49–1.04; \( P = 0.08; \) I² = 0%; Fig. 5) [20, 21, 23, 25–27, 29].

**Subgroup analysis of outcomes by type of GI cancer**

A subgroup analysis evaluating major bleeding events in patients with luminal and nonluminal GI cancer revealed a trend toward nonsignificantly increased major bleeding in patients with luminal GI cancer treated with DOACs, with a pooled RR of 1.22 (95% CI: 0.65–2.30; \( P = 0.54; \) I² = 44%; Fig. 6A) [11, 22, 24, 26–28]. Similarly, among nonluminal GI cancer patients, major bleeding was not significantly different between groups. However, the patients who received DOACs showed a trend toward more major bleeding, with a pooled RR of 1.83 (95% CI: 0.60–5.56; \( P = 0.29; \) I² = 0%; Fig. 6B) [11, 22, 24].

**Subgroup analysis of outcomes by type of study**

Both RCTs and cohort studies were included in this current systematic review and meta-analysis to analyze bleeding outcomes based on the type of study [11, 20–24]. In the case of the RCT studies, the trend of major bleeding outcomes was similar to the pooled analysis. The pooled RRs of major bleeding were 1.65 (95% CI: 0.89–3.08; \( P = 0.11; \) I² = 27%; Fig. 3) [11, 20, 24, 26, 29]. The rate of CRNMB was significantly higher in the DOAC group, with a pooled RR of 2.71 (95% CI: 1.43–5.14; \( P = 0.002; \) I² = 0%; Fig. 4) [11, 24]. The pooled RRs of major bleeding and CRNMB in cohort studies were
| Fist author and year of publication | Patients inclusion criteria | Group of treatment (No.) | Dose of anticoagulants | Type of GI cancers (No.) | Type of GI cancers (luminal VS non-luminal, others) (No.) | Follow up time in months (study period) | Type of study |
|------------------------------------|----------------------------|--------------------------|------------------------|-------------------------|----------------------------------------------------------|----------------------------------------|--------------|
| Young et al 2018 [11]             | Patients with active cancer diagnosis or treatment within 6 months, recurrent or metastatic cancer receiving rivaroxaban or LMWH for symptomatic PE, DVT or incidental PE | Rivaroxaban (91) | 15 mg twice daily for 3 weeks then 20 mg daily | Esophagus (11) | Luminal (70) Non-luminal (21) | 6 months September 2013-December 2016 | Randomized controlled trial |
|                                   |                            | Dalteparin (86)         | 200 IU/Kg once daily for 30 days then 150 IU/Kg | Stomach (4) Pancreas (19) | Luminal (73) Non-luminal (13) |                                        |              |
| Recio-Boiles et al. 2019 [23]     | Patients receiving DOACs or LMWHs with GI cancer and symptomatic or incidental VTE | Rivaroxaban (37) | 15 mg twice daily for 3 weeks then 20 mg daily | Esophagus (3) Stomach (4) Colorectal (26) HB (1) Pancreas (1) | Luminal (33) Non-luminal (29) NET (4) | 6 months up (November 2013-February 2017) | Retrospective cohort study |
|                                   |                            | Apixaban (29)           | 10 mg twice daily for 7 days then 5 mg twice daily | Stomach (4) Pancreas (6) NET (1) | Luminal (16) Non-luminal (21) NET (3) |                                        |              |
| Enoxaparin (40)                   |                            |                          | 1 mg/kg/dose twice daily or 1.5 mg/kg once daily | Stomach (5) Colorectal (11) HB (6) Pancreas (28) | Luminal (109) Non-luminal (94) |                                        |              |
| Lee et al. 2019 [21]              | Patients receiving rivaroxaban or LMWHs with GI cancer and confirmed PE or DVT | Rivaroxaban (78) | 15 mg twice daily for 3 weeks then 20 mg daily | Stomach (19) Colorectal (21) Pancreato-biliary (38) | Luminal (40) Non-luminal (38) | 6 months (January 2012-December 2016) | Retrospective cohort study |
|                                   |                            | LMWH (203) Dalteparin (177) Enoxaparin (25) Nadroparin (1) | Dalteparin: 200 IU/kg once daily Enoxaparin: 1 mg/kg/dose twice daily Nadroparin: 85.5 IU/Kg twice daily | Stomach (98) Colorectal (11) Pancreato-biliary (94) | Luminal (109) Non-luminal (94) |                                        |              |
| Ageno et al. 2020 [24] and Agnelli et al. 2021 [25] Caravaggio study | Patients with active cancer or diagnosed within 2 years receiving apixaban or dalteparin for symptomatic or incidental PE/DVT | Apixaban (188) | 10 mg twice daily for 7 days then 5 mg twice daily | Esophagus (13) Stomach (8) HB (11) Pancreas (33) Colorectal (120) Unknown (2) | Luminal (141) Non-luminal (44) | 6 months (April 2017-June 2019) | Randomized controlled trial (non-inferiority trial) |
|                                   |                            | Dalteparin (187)        | 200 IU/Kg once daily for 30 days then 150 IU/Kg | Stomach (17) HB (9) Pancreas (34) Colorectal (112) Unknown (5) | Luminal (139) Non-luminal (43) |                                        |              |
| Fist author and year of publication | Patients inclusion criteria | Group of treatment (No.) | Dose of anticoagulants | Type of GI cancers (No.) | Type of GI cancers (luminal vs non-luminal, others) (No.) | Follow up time in months (study period) | Type of study |
|-----------------------------------|-----------------------------|--------------------------|------------------------|--------------------------|------------------------------------------------------|------------------------------------------|--------------|
| Mulder et al. 2020 [20]           | Cancer patients with symptomatic or incidental PE/DVT receiving edoxaban or LMWH | Edoxaban (165)           | 60 mg once daily after initial LMWH 5 days (30 mg once daily in creatinine clearance 30–50 mL/min, BMI below 60 kg or concomitant treatment with potent P-glycoprotein inhibitors) Dalteparin (140) | Luminal (116) Non-luminal (49) | 6 months (July 2015-December 2016) | Randomized controlled trial (non-inferiority trial) |
| Kim et al. 2020 [22]              | Patients with upper GI tract and HBP cancer receiving LMWH or rivaroxaban (including unresectable or metastatic cancer) | Rivaroxaban (69)         | 15 mg twice daily for 3 weeks then 20 mg daily | Luminal (24) Non-luminal (45) | 6 months (January 2004-December 2014) | Retrospective cohort study |
| Mokadem et al. 2021 [26]          | Patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy | Apixaban (25)            | 10 mg twice daily for 7 days then 5 mg twice daily | Luminal (23) Non-luminal (2) | 6 months (July 2019-June 2020) | Randomized controlled trial |
| Chen et al. 2021 [27]             | Patients aged 18 years or older with active cancer who developed newly diagnosed VTE DOACs (96) | Enoxaparin (23)          | 1 mg/kg twice daily | Luminal (19) Non-luminal (4) | 12 months (January 2012-January 2019) | Population-based cohort study |
Table 1 (continued)

| Fist author and year of publication | Patients inclusion criteria | Group of treatment (No.) | Dose of anticoagulants | Type of GI cancers (No.) | Type of GI cancers (luminal VS non-luminal, others) (No.) | Follow up time in months (study period) | Type of study |
|-------------------------------------|-----------------------------|--------------------------|------------------------|--------------------------|---------------------------------------------------------|----------------------------------------|--------------|
| Houghton et al. 2021 [28]           | Consecutive GI cancer patients with acute cancer associated VTE | Apixaban (170) Rivaroxaban (93) | Not available | Upper GI (29) Lower GI (103) Pancreas (103) Hepatobiliary (28) | Luminal (132) Non-luminal (131) | 3 and 6 months (March 2013-April 2020) | Prospective cohort study |
|                                     |                             | Enoxaparin (189)         |                        | Upper GI (29) Lower GI (79) Pancreas (59) Hepatobiliary (22) | Luminal (108) Non-luminal (81) |                        |              |
| Kim et al. 2022 [29]                | Patients aged 19–80 years old, with histologically confirmed, advanced upper GI tract, hepatobiliary, and pancreatic cancer, and newly diagnosed (within 2 weeks before randomization) symptomatic or incidental VTE | Apixaban or Rivaroxaban (44) | Apixaban: 10 mg twice daily for 7 days then 5 mg twice daily Rivaroxaban: 15 mg twice daily for 3 weeks then 20 mg daily | Esophagus (8) Stomach (19) Colorectal (6) Pancreas (5) Hepatobiliary (6) | Luminal (27) Non-luminal (17) | Every 1–4 weeks, and then followed up every 3 months for 1 year or until death (August 2017-June 2020) | Randomized controlled trial |
|                                     |                             | Dalteparin (46)          | 200 IU/Kg once daily for 30 days then 150 IU/Kg | Esophagus (5) Stomach (18) Colorectal (1) Pancreas (12) Hepatobiliary (10) | Luminal (24) Non-luminal (22) |                        |              |

Abbreviations: VTE Venous thromboembolism, PE Pulmonary embolism, DVT Deep vein thrombosis, GI Gastrointestinal, HB Hepatobiliary, NET Neuroendocrine tumor, LMWH Low molecular weight heparin
comparable to the full-analysis results (Figs. 3 and 4) [21–23, 27, 28]. Likewise, the pooled RR of VTE recurrence from the RCTs and cohort studies was not different between the DOAC and LMWH groups (Fig. 5) [20, 21, 23, 25–27, 29].
Subgroup analysis of bleeding risk by DOAC type

Neither the rivaroxaban nor the apixaban subgroup was associated with a significant increase in major bleeding events compared with the LMWH arm. For the rivaroxaban group, the pooled RR was 1.40 (95% CI: 0.76–2.59; \(P = 0.29\); \(I^2 = 45\%\); Fig. 7A) [11, 21–23, 28], while for the apixaban group, the pooled RR was 0.93 (95% CI: 0.54–1.63; \(P = 0.81\); \(I^2 = 0\%\); Fig. 7D) [23, 24, 26, 28]. In contrast, CRNMB rates were significantly higher for patients treated with rivaroxaban than for those treated with...
Fig. 5 Forest plot of studies that compared recurrent VTE of the DOAC and LMWH groups.

Fig. 6 Forest plot of studies that compared (A) major bleeding in luminal GI cancer patients and (B) major bleeding in nonluminal GI cancer patients.
LMWHs (pooled RR: 1.82; 95% CI: 1.18–2.81; \( P = 0.007; \) I² = 0%; Fig. 7B) [11, 21, 22]. However, there was no significant difference between the rates of recurrent VTE of the 2 groups (pooled RR: 0.76; 95% CI: 0.25–2.32; \( P = 0.63; \) I² = 0%; Fig. 7C) [21, 23]. Figure 7 presents a forest plot of studies that compared major bleeding, CRNMB, and recurrent VTE in patients who received each DOAC compared with LMWHs.

Due to the limited number of comparative studies of apixaban and LMWHs in GI cancer patients, data specific to CRNMB and recurrent VTE could not be demonstrated. Likewise, analysis of major bleeding, CRNMB, and recurrent VTE could not be performed for the subgroup of GI cancer patients receiving edoxaban due to insufficient data comparing edoxaban and LMWHs.

**Quality assessment**

With the randomized controlled studies, the risk-of-bias assessment revealed some concerns for 4 studies and a high risk of bias for 1 study concerning allocation concealment. Most of the risk-of-bias assessments of the observational studies were moderate, with only 1 study having a serious risk. The risks were related to confounding factors, participant selection, and lack of deviation from the intended intervention report.

**Discussion**

Several studies have demonstrated the efficacy and safety of DOACs in patients with cancer-associated venous thromboembolism [10–13]. As a result, DOACs have become an alternative to LMWHs for the treatment of CAT. Despite the noninferior efficacy of DOACs to LMWHs for preventing recurrent VTE, higher bleeding risks were found with certain DOACs than with LMWHs in subgroup analyses of patients with GI and genitourinary tract cancers [30–32]. However, previous randomized controlled trials enrolled patients with various kinds of cancer. Thus, there is a need for a systematic review and meta-analysis that focuses on DOACs for treating acute venous thromboembolism in patients with gastrointestinal cancer.

The pooled analysis found no significant differences in the major bleeding or the recurrent VTE of the patients receiving DOACs and patients given LMWHs. In addition, major bleeding was similar in the subgroup analysis that compared luminal and nonluminal GI malignancies. In contrast, the rate of CRNMB was significantly higher for patients in the DOAC group than in the LMWH group.

A previous randomized controlled trial of VTE treatment in noncancer patients demonstrated a higher incidence of GI bleeding among patients treated with rivaroxaban than among those treated with warfarin [31]. Moreover, in the SELECT-D study, GI hemorrhage and CRNMB were significantly higher in the rivaroxaban group than in the LMWH group [11]. The Hokusai VTE Cancer trial found a higher rate of major bleeding—but not CRNMB—in patients with cancer receiving edoxaban than in those receiving dalteparin. A higher rate of GI bleeding was also observed in patients with GI cancer [10]. In contrast, 2 studies reported no significant difference in the risk of major GI bleeding in patients with cancer receiving apixaban and those receiving LMWHs [12, 13].

Interestingly, the analysis of bleeding risk and the DOAC type used for acute VTE showed no significant differences in major bleeding in the rivaroxaban and apixaban subgroups. This result suggests that the DOAC type might not be the only high-risk factor for bleeding in patients with GI cancer. Nonetheless, this meta-analysis
observed higher CRNMB in rivaroxaban patients than in LMWH patients.

The meta-analysis results are consistent with previous meta-analyses of DOAC use in cancer patients. Those studies reported higher CRNMB [32] but similar major bleeding events [33, 34] in DOAC users compared with those taking LMWHs. Although the current meta-analysis found no significant difference in the major bleeding rates of patients receiving DOACs and those administered LMWHs, there was a trend toward increased major bleeding in the DOAC group. Moreover, the efficacy of DOACs for preventing recurrent VTE did not differ from that of LMWH. Therefore, DOACs should be considered an effective alternative treatment to LMWH for treating acute VTE, with no statistically significant difference in major bleeding among patients with GI malignancies. However, the significantly higher CRNMB associated with DOACs must be considered when deciding to use DOACs for GI cancer patients. The risk of bleeding should be disclosed and discussed with patients before starting therapy.

Recently, Hussain et al. performed a meta-analysis of the risk of overall bleeding and recurrent VTE in cancer-associated thrombosis treated with factor Xa inhibitors compared with patients treated with LMWHs [35]. However, their meta-analysis had only 3 observational studies in the subgroup analysis of patients with GI cancer [35]. In contrast, our meta-analysis examined 11 studies on patients with GI cancer. Subgroup analyses based on the GI-cancer and DOAC types were also conducted. Analysis for consistency among studies based on visual inspection of forest plots and the low $I^2$ values showed no or low heterogeneity.

This study has some limitations. First, the low number of events and included patients may preclude statistically significant differences in some outcomes, such as recurrent VTE. Second, data were lacking on some baseline patient characteristics that might affect the risk of thrombosis (such as sex, age, cancer treatment, and patient status [inpatient or outpatient]). Third, the definitions of the primary outcomes varied among the included studies. Fourth, only 3 studies included recurrent thrombosis as a primary outcome. Fifth, due to the limited number of studies in the meta-analysis, analytical investigation of heterogeneity could not be evaluated. Last, publication bias could also not be assessed due to the limited number of studies.

Conclusions
The pooled data from this meta-analysis suggest that the efficacy of DOACs for the prevention of recurrent VTE in patients with GI malignancies is comparable to that of LMWHs. Treatment of acute VTE with DOACs is associated with a significantly increased risk of CRNMB but not with a major bleeding risk. Therefore, the benefits and risks of DOAC treatment should be discussed with patients with GI cancer before commencing therapy.

Abbreviations
CAT: Cancer-associated thrombosis; CI: Confidence interval; CRNMB: Clinically relevant nonmajor bleeding; DOACs: Direct oral anticoagulants; GI: Gastrointestinal; ISTH: International Society on Thrombosis and Haemostasis; LMWH: Low-molecular-weight heparin; MB: Major bleeding; RCT: Randomized controlled trial; RR: Relative risk; VTE: Venous thromboembolism.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12959-022-00399-7.

Acknowledgements
Not applicable.

Authors’ contributions
All authors designed the study. TR(1) and WO collected the data. WO performed the statistical analyses. TR(1) and BS drafted the manuscript and prepared the final version. YC, BS, and TR(2) made critical revisions. All authors read and approved the final manuscript.

Funding
The authors received no financial support for this article’s research, authorship, or publication.

Availability of data and materials
The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
As this study did not directly involve human subjects, the need for ethics approval was waived by the institutional review board.

Consent for publication
Not applicable because this study did not directly involve human subjects.

Competing interests
The authors have no personal or professional conflicts of interest to declare, and they received no financial support from the companies that produced or distributed the drugs, devices, or materials described in this report.

Received: 2 September 2021 Accepted: 10 July 2022 Published online: 28 July 2022

References
1. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HW, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–69.
2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4.

3. Walker AJ, Card TR, West J, Crooks C, Grange MJ. Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13.

4. Mahajan A, Brunson A, White R, Wun T. The Epidemiology of cancer-associated venous thromboembolism: An update. Semin Thromb Haemost. 2019;45(4):321–5.

5. Kock VC. Bidirectional risk between venous thromboembolism and cancer in East Asian patients: synthesis of evidence from recent population-based epidemiological studies. Cancer Manag Res. 2017;9:751–9.

6. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21:11.

7. Cancer Research UK. Worldwide cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer. Accessed 20 December 2020.

8. Asmis TR, Templeton M, Trocila R, Pincus N, Randazzio J, Marinela C, et al. Incidence and significance of thromboembolic events (TE) in patients with gastrointestinal (GI) and non-GI malignancies on systemic cytotoxic therapy. J Clin Oncol. 2007;25(Suppl 18):9094–149.

9. Singh R, Soussou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost. 2010;8(8):1879–81.

10. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24.

11. Young AM, Marshall A, Thirwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism. Results of a randomized trial (SELECT-O). J Clin Oncol. 2018;36(20):2017–23.

12. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–21.

13. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–607.

14. Page MJ, McKenzie JE, Bossuyt PM, Bountron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

15. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.

16. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. ROb 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: H498.

17. Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.

18. Borenstein ML,HJ, Rothstein HR. Introduction to meta-analysis. West Sussex: John Wiley & Sons; 2009.

19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):55–70.

20. Mulder FI, van Es N, Kroajiputra A, Fra filo D, Muhl GE, Muhl M, et al. Enoxaparin comparison between non-vitamin k antagonist oral anticoagulants and low molecular-weight heparin in patients with active malignancy and associated venous thromboembolism. World J Gastrointest Oncol. 2019;11(10):866–76.

21. Lee JH, Oh YM, Lee SD, Lee JS. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatic cancer. J Gastrointest Surg. 2018;22(5):1173–80.

22. Kim JH, Yoo C, Seo S, Jeong H, Ryoo BY, Kim KP, et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliiary and pancreatic cancer. PRIORITY. Cancers (Basel). 2022;14(3):559.

23. Raskob GE, van Es N, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118(8):1439–49.

24. Agnelli G, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Mussini G, et al. Bleeding with Apixaban and Dalteparin in patients with cancer-associated venous thromboembolism: Results from the Caravaggio study. Thromb Haemost. 2020;121(5):616–24.

25. Kim JH, Yoo C, Seo S, Jeong H, Ryoo BY, Kim KP, et al. Phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with active malignancy and associated venous thromboembolism. JAMA Netw Open. 2021;4(2): e2036304.

26. Houghton DE, Vlazny DT, Casanegra AI, Brunton N, Froehling DA, Meyer RA, et al. Bleeding in patients with gastrointestinal cancer compared with non-gastrointestinal cancer treated with Apixaban, Rivaroxaban, or Enoxaparin for acute venous thromboembolism. Mayo Clin Proc. 2021;96(11):2793–805.

27. Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, et al. Comparison between non-vitamin k antagonist oral anticoagulants and low molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism. JAMA Netw Open. 2021;4(2):e2036304.

28. Houghton DE, Vlazny DT, Casanegra AI, Brunton N, Froehling DA, Meyer RA, et al. Bleeding in patients with gastrointestinal cancer compared with non-gastrointestinal cancer treated with Apixaban, Rivaroxaban, or Enoxaparin for acute venous thromboembolism. Mayo Clin Proc. 2021;96(11):2793–805.

29. Raskob GE, van Es N, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118(8):1439–49.

30. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.

31. Elbadawi A, Shnoda M, Mahmoud K, Elegindy Y. Efficacy and safety of direct oral anticoagulants versus low molecular weight heparin for cancer related venous thromboembolism: A meta-analysis of randomized trials. Eur Heart J Cardiovasc Pharmacother. 2020. doi:https://doi.org/10.1093/ehjcvp/pvaa067.

32. Tao DL, Olson SR, DeLoughery TG, Shatell J. The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis. Eur J Haematol. 2020;105(3):360–2.

33. Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4(4):550–61.

34. Hussain MR, Ali FS, Verghese D, Myint PT, Ahmed M, Gong Z, et al. Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism: A meta-analysis of randomized controlled trials and non-randomized studies. Crit Rev Oncol Hematol. 2022;169:103526.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.